119 related articles for article (PubMed ID: 38042638)
1. Atherosclerotic Cardiovascular Events in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Retrospective Cohort Study.
Tan S; Spear E; Sane N; Chan J; Nelson AJ; Alamgeer M; Nerlekar N; Segelov E; Nicholls SJ
Heart Lung Circ; 2024 May; 33(5):721-729. PubMed ID: 38042638
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitors in cancer: the increased risk of atherosclerotic cardiovascular disease events and progression of coronary artery calcium.
Gong B; Guo Y; Li Y; Wang J; Zhou G; Chen YH; Nie T; Yang M; Luo K; Zheng C; Pan F; Liang B; Yang L
BMC Med; 2024 Jan; 22(1):44. PubMed ID: 38291431
[TBL] [Abstract][Full Text] [Related]
3. Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque.
Drobni ZD; Alvi RM; Taron J; Zafar A; Murphy SP; Rambarat PK; Mosarla RC; Lee C; Zlotoff DA; Raghu VK; Hartmann SE; Gilman HK; Gong J; Zubiri L; Sullivan RJ; Reynolds KL; Mayrhofer T; Zhang L; Hoffmann U; Neilan TG
Circulation; 2020 Dec; 142(24):2299-2311. PubMed ID: 33003973
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer.
Chitturi KR; Xu J; Araujo-Gutierrez R; Bhimaraj A; Guha A; Hussain I; Kassi M; Bernicker EH; Trachtenberg BH
JACC CardioOncol; 2019 Dec; 1(2):182-192. PubMed ID: 34396181
[TBL] [Abstract][Full Text] [Related]
5. Cancer type and histology influence cutaneous immunotherapy toxicities: a multi-institutional cohort study.
Wan G; Khattab S; Leung BW; Zhang S; Nguyen N; Tran M; Lin C; Chang C; Alexander N; Jairath R; Phillipps J; Tang K; Rajeh A; Zubiri L; Chen ST; Demehri S; Yu KH; Gusev A; Kwatra SG; LeBoeuf NR; Reynolds KL; Semenov YR
Br J Dermatol; 2024 Jun; 191(1):117-124. PubMed ID: 38366637
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular Risk in Cancer Patients Treated with Immune Checkpoint Inhibitors: Challenges and Future Directions.
Tan S; Nelson AJ; Muthalaly RG; Ramkumar S; Hamilton J; Nerlekar N; Segelov E; Nicholls SJ
Eur J Prev Cardiol; 2024 Jun; ():. PubMed ID: 38870247
[TBL] [Abstract][Full Text] [Related]
7. Is carotid artery evaluation necessary for primary prevention in asymptomatic high-risk patients without atherosclerotic cardiovascular disease?
Kim G; Youn HJ; Choi YS; Jung HO; Chung WS; Kim CM
Clin Interv Aging; 2015; 10():1111-9. PubMed ID: 26185430
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular adverse events associated with immune checkpoint inhibitors: A retrospective multicenter cohort study.
Zheng Y; Chen Z; Song W; Xu Y; Zhao Z; Sun Y; Wang Y; Geng X; Zhao J; Zhang X; Xu Y; Chan JSK; Tse G; Li G; Hong L; Liu T
Cancer Med; 2024 May; 13(10):e7233. PubMed ID: 38752474
[TBL] [Abstract][Full Text] [Related]
9. Blood pressure surveillance in cancer patients treated with immune checkpoint inhibitors.
Tan S; Spear E; Sane N; Nelson AJ; Nerlekar N; Segelov E; Nicholls SJ
J Hum Hypertens; 2023 Nov; 37(11):1043-1046. PubMed ID: 37076569
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States.
Jain P; Gutierrez Bugarin J; Guha A; Jain C; Patil N; Shen T; Stanevich I; Nikore V; Margolin K; Ernstoff M; Velcheti V; Barnholtz-Sloan J; Dowlati A
ESMO Open; 2021 Oct; 6(5):100252. PubMed ID: 34461483
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular risk factor reporting in immune checkpoint inhibitor trials: A systematic review.
Tan S; Sivakumar S; Segelov E; Nicholls SJ; Nelson AJ
Cancer Epidemiol; 2023 Apr; 83():102334. PubMed ID: 36669376
[TBL] [Abstract][Full Text] [Related]
12. Assessment and Management of Cardiovascular Risk Factors Among US Veterans With Prostate Cancer.
Sun L; Parikh RB; Hubbard RA; Cashy J; Takvorian SU; Vaughn DJ; Robinson KW; Narayan V; Ky B
JAMA Netw Open; 2021 Feb; 4(2):e210070. PubMed ID: 33625512
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Disease Risk Assessment Using Traditional Risk Factors and Polygenic Risk Scores in the Million Veteran Program.
Vassy JL; Posner DC; Ho YL; Gagnon DR; Galloway A; Tanukonda V; Houghton SC; Madduri RK; McMahon BH; Tsao PS; Damrauer SM; O'Donnell CJ; Assimes TL; Casas JP; Gaziano JM; Pencina MJ; Sun YV; Cho K; Wilson PWF
JAMA Cardiol; 2023 Jun; 8(6):564-574. PubMed ID: 37133828
[TBL] [Abstract][Full Text] [Related]
14. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
15. Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA).
Budoff MJ; Young R; Burke G; Jeffrey Carr J; Detrano RC; Folsom AR; Kronmal R; Lima JAC; Liu KJ; McClelland RL; Michos E; Post WS; Shea S; Watson KE; Wong ND
Eur Heart J; 2018 Jul; 39(25):2401-2408. PubMed ID: 29688297
[TBL] [Abstract][Full Text] [Related]
16. Incidence of Cardiovascular Events in Patients Treated With Immune Checkpoint Inhibitors.
Laenens D; Yu Y; Santens B; Jacobs J; Beuselinck B; Bechter O; Wauters E; Staessen J; Janssens S; Van Aelst L
J Clin Oncol; 2022 Oct; 40(29):3430-3438. PubMed ID: 35772044
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular events after cancer immunotherapy as oncologic emergencies: Analyses of 610 head and neck cancer patients treated with immune checkpoint inhibitors.
Reyes-Gibby CC; Qdaisat A; Ferrarotto R; Fadol A; Bischof JJ; Coyne CJ; Lipe DN; Hanna EY; Shete S; Abe JI; Yeung SJ
Head Neck; 2024 Mar; 46(3):627-635. PubMed ID: 38151809
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Large-Scale Proteomics for Prediction of Cardiovascular Events.
Helgason H; Eiriksdottir T; Ulfarsson MO; Choudhary A; Lund SH; Ivarsdottir EV; Hjorleifsson Eldjarn G; Einarsson G; Ferkingstad E; Moore KHS; Honarpour N; Liu T; Wang H; Hucko T; Sabatine MS; Morrow DA; Giugliano RP; Ostrowski SR; Pedersen OB; Bundgaard H; Erikstrup C; Arnar DO; Thorgeirsson G; Masson G; Magnusson OT; Saemundsdottir J; Gretarsdottir S; Steinthorsdottir V; Thorleifsson G; Helgadottir A; Sulem P; Thorsteinsdottir U; Holm H; Gudbjartsson D; Stefansson K
JAMA; 2023 Aug; 330(8):725-735. PubMed ID: 37606673
[TBL] [Abstract][Full Text] [Related]
19. Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults.
Schonfeld SJ; Tucker MA; Engels EA; Dores GM; Sampson JN; Shiels MS; Chanock SJ; Morton LM
JAMA Netw Open; 2022 Mar; 5(3):e223461. PubMed ID: 35315916
[TBL] [Abstract][Full Text] [Related]
20. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.
Sussman TA; Li H; Hobbs B; Funchain P; McCrae KR; Khorana AA
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
